Aisling Capital
North America, New York, United States, New York
Description
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Investor Profile
Aisling Capital has made 120 investments, with 2 in the past 12 months and 23% as lead.
Stage Focus
- Series B (23%)
- Series C (21%)
- Series Unknown (15%)
- Series A (13%)
- Post Ipo Equity (12%)
- Series D (9%)
- Private Equity (3%)
- Series E (3%)
- Debt Financing (2%)
- Post Ipo Debt (1%)
Country Focus
- United States (91%)
- United Kingdom (3%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- Switzerland (3%)
- China (1%)
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
- Canada (1%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Therapeutics
- Medical
- Medical Device
- Biopharma
- Life Science
- Manufacturing
- Clinical Trials
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
